Ascelia Pharma AB ACE
OMXSTO · Sweden · Health Technology
SEK 0.7990+0.01 (+0.88%)
Market closed· · SEK · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · SEK · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
MALMÖ, SE / ACCESS Newswire / September 24, 2026 / AB (publ) (STO:ACE), a biotech company focused on improving the lives of people living with rare cancer conditions, today announced the publication of a peer-reviewed article related to Orviglance® in the Journal of Magnetic Resonance Imaging (JMRI), one of the leading peer-reviewed journals in the field of magnetic resonance imaging.The article, titled "Pharmacokinetics and Pharmacodynamics of a Single Oral Dose of Ascelia-Manganese-Based MRI C
MALMÖ, SE / ACCESS Newswire / September 10, 2026 / (STO:ACE) completed the previously scheduled Type A meeting with the U. Food and Drug Administration (FDA) on September 9, 2026, regarding the Complete Response Letter (CRL) for the Orviglance® New Drug Application (NDA).
Despite a surprise complete response letter, Ascelia Pharma remains confident in Orviglans' approval path, with a pivotal FDA Type A meeting set for September 9th and partnership interest intact.
MALMÖ, SE / ACCESS Newswire / August 17, 2026 / Ascelia Pharma AB (publ) (STO:ACE), a biotech company focused on improving the lives of people living with rare cancer conditions, today announced that the U.S. Food and Drug Administration (FDA) has ...
MALMÖ, SE / ACCESS Newswire / July 15, 2026 / Ascelia Pharma (STO:ACE), a biotech company focused on improving the lives of people with rare cancer conditions, today announces that CFO Anton Hansson will be leaving the Company. In connection with ...
MALMÖ, SE / ACCESS Newswire / July 12, 2026 / Ascelia Pharma (STO:ACE) - Ascelia Pharma AB (publ) (STO:ACE), a biopharmaceutical company focused on improving the lives of people living with rare cancer conditions, provides an update following the ...
Ascelia Pharma AB (FRA:7ZA) advances towards FDA approval for Orbiglanz while navigating financial hurdles and strategic partnerships.
MALMÖ, SE / ACCESS Newswire / April 30, 2026 / Ascelia Pharma (STO:ACE): During April, the registered number of shares and votes in Ascelia Pharma AB ("Ascelia Pharma") has increased due to the directed new issue of ordinary shares which was announced ...
The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. MALMÖ, SE / ACCESS Newswire / April 9, 2026 / Ascelia Pharma (STO:ACE) today published ...
The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. MALMÖ, SE / ACCESS Newswire / March 30, 2026 / Ascelia Pharma (STO:ACE) - The shareholders ...
MALMÖ, SE / ACCESS Newswire / March 27, 2026 / Ascelia Pharma (STO:ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced that an abstract with an evaluation of the detection of focal liver lesions ...
Ascelia Pharma AB (FRA:7ZA) anticipates FDA decision on Origlans by July 2026, while navigating partnership and financial hurdles.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.